Cargando…
Diagnosis and management of microscopic colitis: current perspectives
Collagenous colitis and lymphocytic colitis, together constituting microscopic colitis, are common causes of chronic diarrhea. They are characterized clinically by chronic nonbloody diarrhea and a macroscopically normal colonic mucosa where characteristic histopathological findings are seen. Previou...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144984/ https://www.ncbi.nlm.nih.gov/pubmed/25170275 http://dx.doi.org/10.2147/CEG.S63905 |
_version_ | 1782332112816308224 |
---|---|
author | Bohr, Johan Wickbom, Anna Hegedus, Agnes Nyhlin, Nils Hultgren Hörnquist, Elisabeth Tysk, Curt |
author_facet | Bohr, Johan Wickbom, Anna Hegedus, Agnes Nyhlin, Nils Hultgren Hörnquist, Elisabeth Tysk, Curt |
author_sort | Bohr, Johan |
collection | PubMed |
description | Collagenous colitis and lymphocytic colitis, together constituting microscopic colitis, are common causes of chronic diarrhea. They are characterized clinically by chronic nonbloody diarrhea and a macroscopically normal colonic mucosa where characteristic histopathological findings are seen. Previously considered rare, they now have emerged as common disorders that need to be considered in the investigation of the patient with chronic diarrhea. The annual incidence of each disorder is five to ten per 100,000 inhabitants, with a peak incidence in 60- to 70-year-old individuals and a predominance of female patients in collagenous colitis. The etiology and pathophysiology are not well understood, and the current view suggests an uncontrolled mucosal immune reaction to various luminal agents in predisposed individuals. Clinical symptoms comprise chronic diarrhea, abdominal pain, fatigue, weight loss, and fecal incontinence that may impair the patient’s health-related quality of life. An association is reported with other autoimmune disorders, such as celiac disease, thyroid disorders, diabetes mellitus, and arthritis. The best-documented treatment, both short-term and long-term, is budesonide, which induces clinical remission in up to 80% of patients after 8 weeks’ treatment. However, after successful budesonide therapy is ended, recurrence of clinical symptoms is common, and the best possible long-term management deserves further study. The long-term prognosis is good, and the risk of complications, including colonic cancer, is low. We present an update of the epidemiology, pathogenesis, diagnosis, and management of microscopic colitis. |
format | Online Article Text |
id | pubmed-4144984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41449842014-08-28 Diagnosis and management of microscopic colitis: current perspectives Bohr, Johan Wickbom, Anna Hegedus, Agnes Nyhlin, Nils Hultgren Hörnquist, Elisabeth Tysk, Curt Clin Exp Gastroenterol Review Collagenous colitis and lymphocytic colitis, together constituting microscopic colitis, are common causes of chronic diarrhea. They are characterized clinically by chronic nonbloody diarrhea and a macroscopically normal colonic mucosa where characteristic histopathological findings are seen. Previously considered rare, they now have emerged as common disorders that need to be considered in the investigation of the patient with chronic diarrhea. The annual incidence of each disorder is five to ten per 100,000 inhabitants, with a peak incidence in 60- to 70-year-old individuals and a predominance of female patients in collagenous colitis. The etiology and pathophysiology are not well understood, and the current view suggests an uncontrolled mucosal immune reaction to various luminal agents in predisposed individuals. Clinical symptoms comprise chronic diarrhea, abdominal pain, fatigue, weight loss, and fecal incontinence that may impair the patient’s health-related quality of life. An association is reported with other autoimmune disorders, such as celiac disease, thyroid disorders, diabetes mellitus, and arthritis. The best-documented treatment, both short-term and long-term, is budesonide, which induces clinical remission in up to 80% of patients after 8 weeks’ treatment. However, after successful budesonide therapy is ended, recurrence of clinical symptoms is common, and the best possible long-term management deserves further study. The long-term prognosis is good, and the risk of complications, including colonic cancer, is low. We present an update of the epidemiology, pathogenesis, diagnosis, and management of microscopic colitis. Dove Medical Press 2014-08-21 /pmc/articles/PMC4144984/ /pubmed/25170275 http://dx.doi.org/10.2147/CEG.S63905 Text en © 2014 Bohr et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Bohr, Johan Wickbom, Anna Hegedus, Agnes Nyhlin, Nils Hultgren Hörnquist, Elisabeth Tysk, Curt Diagnosis and management of microscopic colitis: current perspectives |
title | Diagnosis and management of microscopic colitis: current perspectives |
title_full | Diagnosis and management of microscopic colitis: current perspectives |
title_fullStr | Diagnosis and management of microscopic colitis: current perspectives |
title_full_unstemmed | Diagnosis and management of microscopic colitis: current perspectives |
title_short | Diagnosis and management of microscopic colitis: current perspectives |
title_sort | diagnosis and management of microscopic colitis: current perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144984/ https://www.ncbi.nlm.nih.gov/pubmed/25170275 http://dx.doi.org/10.2147/CEG.S63905 |
work_keys_str_mv | AT bohrjohan diagnosisandmanagementofmicroscopiccolitiscurrentperspectives AT wickbomanna diagnosisandmanagementofmicroscopiccolitiscurrentperspectives AT hegedusagnes diagnosisandmanagementofmicroscopiccolitiscurrentperspectives AT nyhlinnils diagnosisandmanagementofmicroscopiccolitiscurrentperspectives AT hultgrenhornquistelisabeth diagnosisandmanagementofmicroscopiccolitiscurrentperspectives AT tyskcurt diagnosisandmanagementofmicroscopiccolitiscurrentperspectives |